XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$3.65
-0.29 (-7.36%)
▼
5d:
-18.89%
30d:
-14.92%
90d:
+17.74%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XFOR is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XFOR is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $3.65, which is considered oversold relative to its 30-day fair value range of $4.02 to $4.35.
Technical Outlook: Technically, XFOR is in a uptrend. The price is currently testing key support at $3.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.67 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XFOR is in a uptrend. The price is currently testing key support at $3.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.67 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.02 -
$4.35
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- BULLISH: Trading 196.1% below Wall St target ($11.67)
- WARNING: Recommendation downgraded due to -18.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.02 -
$4.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.68
Resistance Level
$4.60
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.38
Wall Street Target
$11.67
(+196.1%)
Revenue Growth (YoY)
-90.6%
Share & Embed Analysis
Last updated: May 18, 2026 1:04 PM ET
Data refreshes hourly during market hours. Next update: 2:04 PM
Data refreshes hourly during market hours. Next update: 2:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
